Pfiz­er backs $60M in­fu­sion in­to Car­rick, teams up on breast can­cer treat­ment

In a big week for Car­rick Ther­a­peu­tics, the com­pa­ny an­nounced $60 mil­lion in fund­ing for its lead breast can­cer drug and de­vel­op­ment of a sec­ond pro­gram, as well as a col­lab­o­ra­tion with Pfiz­er for com­bo de­vel­op­ment.

The $35 mil­lion from Pfiz­er comes with an agree­ment un­der which Pfiz­er will sup­port Car­rick’s Phase II study of samu­raci­clib in com­bi­na­tion with As­traZeneca’s Faslodex for ad­vanced breast can­cer. Along with the in­vest­ment, Adam Schay­owitz, vice pres­i­dent and de­vel­op­ment head of breast can­cer, col­orec­tal can­cer and melanoma at Pfiz­er glob­al prod­uct de­vel­op­ment, will join Car­rick’s sci­en­tif­ic ad­vi­so­ry board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER